Document Type : Research Articles
Authors
- Younes Aftabi 1
- Habib Zarredar 2
- Mohammadreza Sheikhi 3
- Zahra Khoshkam 3
- Abasalt Hosseinzadeh Colagar 4
1 Tabriz University of Medical Sciences; University of Mazandaran, Babolsar, Mazandaran
2 Tabriz University of Medical Sciences, Tabriz, Iran
3 University of Tehran, Tehran, Iran
4 University of Mazandaran, Babolsar, Mazandaran, Iran
Abstract
Aryl hydrocarbon receptor (AHR) is a ligand-activated transcription factor and its induction may result in suppressing of cell proliferation in colorectal cancer (CRC). Cucurbitacin D (CucD), E (CucE) and I (CucI) are plant derived metabolites that inhibit cancer cells. This study aimed to evaluate the possible potency of the cucurbitacins for activation of AHR expression in CRC cell lines SW-480 and HT-29. The MTT assay was used to find the LC50 value of the metabolites in the cell lines. Afterward, the cells incubated with the LC50 concentrations and AHR-mRNA expression assessed using RT-PCR. The LC50 values of CucD, CucE, and CucI were 4.5, 6.8, and 3.8 μM in HT-29 cell line and 35, 19, 17.5 μM in SW-480 cells respectively. The SW-480 cells were more resistant against Cucs in comparison with HT-29 cells and all three Cucs cause to more AHR-mRNA expression in HT-29 cells. CucE had the lowest effect on AHR-mRNA expression in the cell lines and CucI was a common metabolite for both HT-29 and SW-480 cells, which showed the lowest LC50 value (the highest toxicity) and the highest effect on AHR-mRNA expression. CucI may have a potential to be used as an activator of AHR expression in CRC studies.
Keywords
Abbas S., Vincourt J. B., Habib L., Netter P., Greige-Gerges H. and Magdalou J. (2013) The cucurbitacins E, D and I: investigation of their cytotoxicity toward human chondrosarcoma SW 1353 cell line and their biotransformation in man liver. Toxicology letters 216:189-199.
Abdelrahim M., Ariazi E., Kim K., Khan S., Barhoumi R., Burghardt R., Liu S., Hill D., Finnell R., Wlodarczyk B. and Jordan, V. C. (2006) 3-Methylcholanthrene and other aryl hydrocarbon receptor agonists directly activate estrogen receptor α. Cancer research 66:2459-2467.
Alghasham A. A. (2013) Cucurbitacins–a promising target for cancer therapy. International journal of health sciences 7:77.
Arnold M., Sierra M. S., Laversanne M., Soerjomataram I., Jemal A. and Bray F. (2017) Global patterns and trends in colorectal cancer incidence and mortality. Gut 66:683-691.
Blaskovich M. A., Sun J., Cantor A., Turkson J., Jove R. and Sebti S. M. (2003) Discovery of JSI-124 (cucurbitacin I), a selective Janus kinase/signal transducer and activator of transcription 3 signaling pathway inhibitor with potent antitumor activity against human and murine cancer cells in mice. Cancer research 63:1270-1279.
Chan K. T., Meng F. Y., Li Q., Ho C. Y., Lam T. S., To Y., Lee W. H., Li M., Chu K. H. and Toh M. (2010) Cucurbitacin B induces apoptosis and S phase cell cycle arrest in BEL-7402 human hepatocellular carcinoma cells and is effective via oral administration. Cancer letters 294:118-124.
Chen I., Hsieh T., Thomas T. and Safe, S. (2001) Identification of estrogen-induced genes downregulated by AhR agonists in MCF-7 breast cancer cells using suppression subtractive hybridization. Gene 262:207-214.
Chen X., Bao J., Guo J., Ding Q., Lu J., Huang M. and Wang Y. (2012) Biological activities and potential molecular targets of cucurbitacins: a focus on cancer. Anti-cancer drugs 23:777-787.
Denison M. S. and van den Berg M. (2017) Editorial overview: The aryl hydrocarbon (Ah) receptor: From toxicology to human health. Current opinion in toxicology 2:i-iv.
Diaz-Diaz C. J., Ronnekleiv-Kelly S. M., Nukaya M., Geiger P. G., Balbo S., Dator R., Megna B. W., Carney P. R., Bradfield C. A. and Kennedy G.D. (2016) The Aryl Hydrocarbon Receptor is a Repressor of Inflammation-associated Colorectal Tumorigenesis in Mouse. Annals of surgery 264:429-436.
Edmondson J. M., Armstrong L. S. and Martinez A. O. (1988) A rapid and simple MTT-based spectrophotometric assay for determining drug sensitivity in monolayer cultures. Journal of tissue culture methods 11:15-17.
Ehrlich A. K. and Kerkvliet N. I. (2017) Is chronic AhR activation by rapidly metabolized ligands safe for the treatment of immune-mediated diseases?. Current opinion in toxicology 2:72-78.
Esser C. and Rannug A. (2015) The aryl hydrocarbon receptor in barrier organ physiology, immunology, and toxicology. Pharmacological reviews 67:259-279.
Fan Y., Boivin G. P., Knudsen E. S., Nebert D. W., Xia Y. and Puga A. (2010) The aryl hydrocarbon receptor functions as a tumor suppressor of liver carcinogenesis. Cancer research 70:212-220.
Feng H., Zang L., Zhao Z. X. and Kan Q. C. (2014) Cucurbitacin-E inhibits multiple cancer cells proliferation through attenuation of Wnt/β-catenin signaling. Cancer biotherapy and radiopharmaceuticals 29:210-214.
Gluschnaider U., Hidas G., Cojocaru G., Yutkin V., Ben-Neriah Y. and Pikarsky E. (2010) β-TrCP inhibition reduces prostate cancer cell growth via upregulation of the aryl hydrocarbon receptor. PloS one 5:e9060.
Goettel J. A., Gandhi R., Kenison J. E., Yeste A., Murugaiyan G., Sambanthamoorthy S., Griffith A. E., Patel B., Shouval D. S., Weiner H. L. and Snapper S.B. (2016) AHR activation is protective against colitis driven by T cells in humanized mice. Cell reports 17:1318-1329.
Hall J. M., Barhoover M. A., Kazmin D., McDonnell D. P., Greenlee W. F. and Thomas, R. S. (2010) Activation of the aryl-hydrocarbon receptor inhibits invasive and metastatic features of human breast cancer cells and promotes breast cancer cell differentiation. Molecular endocrinology 24:359-369.
Hsu Y. C., Huang T. Y. and Chen M. J. (2014) Therapeutic ROS targeting of GADD45γ in the induction of G2/M arrest in primary human colorectal cancer cell lines by cucurbitacin E. Cell death & disease 5:e1198.
Ikuta T., Kobayashi Y., Kitazawa M., Shiizaki K., Itano N., Noda T., Pettersson S., Poellinger L., Fujii-Kuriyama Y., Taniguchi S.I. and Kawajiri K. (2013) ASC-associated inflammation promotes cecal tumorigenesis in aryl hydrocarbon receptor-deficient mice. Carcinogenesis 34:1620-1627.
Ikuta T., Kurosumi M., Yatsuoka T. and Nishimura Y. (2016) Tissue distribution of aryl hydrocarbon receptor in the intestine: Implication of putative roles in tumor suppression. Experimental cell research 343:126-134.
Iskar M., Campillos M., Kuhn M., Jensen L. J., Van Noort V. and Bork, P. (2010) Drug-induced regulation of target expression. PLoS computational biology 6:e1000925.
Jafargholizadeh N., Zargar S. J. and Aftabi Y. (2018) The cucurbitacins D, E, and I from Ecballium elaterium (L.) upregulate the LC3 gene and induce cell-cycle arrest in human gastric cancer cell line AGS. Iranian journal of basic medical sciences 21:253.
Jayaprakasam B., Seeram N. P. and Nair M. G. (2003) Anticancer and antiinflammatory activities of cucurbitacins from Cucurbitaandreana. Cancer letters 189:11-16.
Jevtić B., Djedović N., Stanisavljević S., Despotović J., Miljković D. and Timotijević G. (2016) Cucurbitacin E potently modulates the activity of encephalitogenic cells. Journal of agricultural and food chemistry 64:4900-4907.
Jin U. H., Lee S. O., Pfent C. and Safe S. (2014) The aryl hydrocarbon receptor ligand omeprazole inhibits breast cancer cell invasion and metastasis. BMC cancer 14:498.
Kaushik U., Aeri V. and Mir S. R. (2015) Cucurbitacins–an insight into medicinal leads from nature. Pharmacognosy reviews 9:12.
Kawajiri K. and Fujii-Kuriyama Y. (2007) Cytochrome P450 gene regulation and physiological functions mediated by the aryl hydrocarbon receptor. Archives of biochemistry and biophysics 464:207-212.
Kawajiri K., Kobayashi Y., Ohtake F., Ikuta T., Matsushima Y., Mimura J., Pettersson S., Pollenz R. S., Sakaki T., Hirokawa T. and Akiyama T. (2009) Aryl hydrocarbon receptor suppresses intestinal carcinogenesis in ApcMin/+ mice with natural ligands. Proceedings of the national academy of sciences 106:13481-13486.
Kim H. J., Park J. H. Y. and Kim J. K. (2014) Cucurbitacin-I, a natural cell-permeable triterpenoid isolated from Cucurbitaceae, exerts potent anticancer effect in colon cancer. Chemico-biological interactions 219:1-8.
Koliopanos A., Kleeff J., Xiao Y., Safe S., Zimmermann A., Büchler M. W. and Friess H. (2002) Increased arylhydrocarbon receptor expression offers a potential therapeutic target for pancreatic cancer. Oncogene 21:6059.
Kolluri S. K., Jin U. H. and Safe S. (2017) Role of the aryl hydrocarbon receptor in carcinogenesis and potential as an anti-cancer drug target. Archives of toxicology 91:2497-2513.
Lee D. H., Iwanski G. B. and Thoennissen N. H. (2010) Cucurbitacin: ancient compound shedding new light on cancer treatment. The scientific world journal 10:413-418.
Levine-Fridman A., Chen L. and Elferink C. J. (2004) Cytochrome P4501A1 promotes G1 phase cell cycle progression by controlling aryl hydrocarbon receptor activity. Molecular pharmacology 65:461-469.
Li W., Harper P. A., Tang B. K. and Okey A. B. (1998) Regulation of cytochrome P450 enzymes by aryl hydrocarbon receptor in human cells: CYP1A2 expression in the LS180 colon carcinoma cell line after treatment with 2, 3, 7, 8-tetrachlorodibenzo-p-dioxin or 3-methylcholanthrene. Biochemical pharmacology 56:599-612.
Litzenburger U. M., Opitz C. A., Sahm F., Rauschenbach K. J., Trump S., Winter M., Ott M., Ochs K., Lutz C., Liu X. and Anastasov N. (2014) Constitutive IDO expression in human cancer is sustained by an autocrine signaling loop involving IL-6, STAT3 and the AHR. Oncotarget 5:1038.
Liu H., Ramachandran I. and Gabrilovich D. I. (2014) Regulation of plasmacytoid dendritic cell development in mice by aryl hydrocarbon receptor. Immunology and cell biology 92:200-203.
Maayah Z. H., El-Gendy M. A., El-Kadi A. O. and Korashy H. M. (2013) Sunitinib, a tyrosine kinase inhibitor, induces cytochrome P450 1A1 gene in human breast cancer MCF7 cells through ligand-independent aryl hydrocarbon receptor activation. Archives of toxicology 87:847-856.
Marlowe J. L. and Puga A. (2005) Aryl hydrocarbon receptor, cell cycle regulation, toxicity, and tumorigenesis. Journal of cellular biochemistry 96:1174-1184.
Megna B. W., Carney P. R., Depke M. G., Nukaya M., McNally J., Larsen L., Rosengren R. J. and Kennedy G.D. (2017) The aryl hydrocarbon receptor as an antitumor target of synthetic curcuminoids in colorectal cancer. Journal of surgical research 213:16-24.
Morrow D., Qin C., Smith III, R. and Safe, S. (2004) Aryl hydrocarbon receptor-mediated inhibition of LNCaP prostate cancer cell growth and hormone-induced transactivation. The Journal of steroid biochemistry and molecular biology 88:27-36.
Nebert D. W., Dalton T. P., Okey A. B. and Gonzalez F. J. (2004) Role of aryl hydrocarbon receptor-mediated induction of the CYP1 enzymes in environmental toxicity and cancer. Journal of biological chemistry 279:23847-23850.
Nebert D. W., Roe A. L., Dieter M. Z., Solis W. A., Yang Y. I. and Dalton T. P. (2000) Role of the aromatic hydrocarbon receptor and [Ah] gene battery in the oxidative stress response, cell cycle control, and apoptosis. Biochemical pharmacology 59:65-85.
Nguyen N. T., Nakahama T., Le D. H., Van Son L., Chu H. H. and Kishimoto T. (2014) Aryl hydrocarbon receptor and kynurenine: recent advances in autoimmune disease research. Frontiers in immunology 5:551.
Novotna A., Korhonova M., Bartonkova I., Soshilov A. A., Denison M. S., Bogdanova K., Kolar M., Bednar P. and Dvorak Z. (2014) Enantiospecific effects of ketoconazole on aryl hydrocarbon receptor. Plos one 9: e101832.
O’Donnell E. F., Jang H. S., Pearce M., Kerkvliet N. I. and Kolluri S. K. (2017) The aryl hydrocarbon receptor is required for induction of p21cip1/waf1 expression and growth inhibition by SU5416 in hepatoma cells. Oncotarget 8:25211.
Oh-oka K., Kojima Y., Uchida K., Yoda K., Ishimaru K., Nakajima S., Hemmi J., Kano H., Fujii-Kuriyama Y., Katoh R. and Ito, H. (2017) Induction of colonic regulatory T cells by mesalamine by activating the aryl hydrocarbon receptor. Cellular and molecular gastroenterology and hepatology 4:135-151.
Platten M., von Knebel Doeberitz N., Oezen I., Wick W. and Ochs, K. (2015) Cancer immunotherapy by targeting IDO1/TDO and their downstream effectors. Frontiers in immunology 5:673.
Qiang M. A., Kinneer K., Yongyi B. I. and KAN, Y. W. (2004) Induction of murine NAD (P) H: quinone oxidoreductase by 2, 3, 7, 8-tetrachlorodibenzo-p-dioxin requires the CNC (cap n collar) basic leucine zipper transcription factor Nrf2 (nuclear factor erythroid 2-related factor 2): cross-interaction between AhR (aryl hydrocarbon receptor) and Nrf2 signal transduction. Biochemical journal 377:205-213.
Ronnekleiv-Kelly S. M., Nukaya M., Diaz-Diaz C. J., Megna B. W., Carney P. R., Geiger P. G. and Kennedy G. D. (2016) Aryl hydrocarbon receptor-dependent apoptotic cell death induced by the flavonoid chrysin in human colorectal cancer cells. Cancer letters 370:91-99.
Safe S., Wormke M. and Samudio, I. (2000) Mechanisms of inhibitory aryl hydrocarbon receptor-estrogen receptor crosstalk in human breast cancer cells. Journal of mammary gland biology and neoplasia 5:295-306.
Song J., Liu H., Li Z., Yang C. and Wang C. (2015) Cucurbitacin I inhibits cell migration and invasion and enhances chemosensitivity in colon cancer. Oncology reports 33:1867-1871.
Stockinger B., Meglio P. D., Gialitakis M. and Duarte J. H. (2014) The aryl hydrocarbon receptor: multitasking in the immune system. Annual review of immunology 32:403-432.
Tsai C. H., Li C. H., Cheng Y. W., Lee C. C., Liao P. L., Lin C. H., Huang S. H. and Kang J.J. (2017) The inhibition of lung cancer cell migration by AhR-regulated autophagy. Scientific reports 7:41927.
Wang Z., Monti S. and Sherr D. H. (2017) The diverse and important contributions of the AHR to cancer and cancer immunity. Current opinion in toxicology 2:93-102.
Xie G. and Raufman J. P. (2015) Role of the aryl hydrocarbon receptor in colon neoplasia. Cancers 7:1436-1446.
)
Send comment about this article